glp-1 asa Advises No Longer Holding Agents Prior to Surgery for Most Patients Reflections on the discovery GLP-1

It is crucial to note that this formulation should not be used in combination with other topical medications, as it may increase the risk of adverse reactions

Mild side effects such as flushing or nausea can occur, though these are typically short-lived and diminish as the body adapts to treatment

Clinical Evidence In a 2021 clinical trial (SURPASS-2), tirzepatide was found to have greater reductions in hemoglobin A1c (HbA1c) and body weight than semaglutide 1 mg in people with type 2 diabetes [6]

All patients gave a written informed consent and the human sample collection was approved by the Ethics Committee of Zhongshan Hospital, Fudan University